

Laurie H Sehn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8072166/publications.pdf>

Version: 2024-02-01

142
papers

11,203
citations

47409

49
h-index

35168

102
g-index

142
all docs

142
docs citations

142
times ranked

9163
citing authors

#	ARTICLE	IF	CITATIONS
1	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	2.5	77
2	Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. <i>Blood Advances</i> , 2022, 6, 1651-1660.	2.5	14
3	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	0.8	160
4	Limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 822-834.	0.6	22
5	CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?. <i>Blood</i> , 2022, 139, 2737-2746.	0.6	60
6	A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA. <i>EJHaem</i> , 2022, 3, 406-414.	0.4	6
7	Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	0
8	Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia. <i>British Journal of Haematology</i> , 2022, 198, 684-692.	1.2	4
9	A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies. <i>Current Oncology</i> , 2022, 29, 3940-3949.	0.9	7
10	Revising the Treatment Pathways in Lymphoma: New Standards of Care—How Do We Choose?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 629-642.	1.8	2
11	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 1055-1065.	5.1	119
12	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. <i>Blood</i> , 2021, 137, 2196-2208.	0.6	18
13	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 267-278.e10.	0.2	8
14	Primary mediastinal large B-cell lymphoma. <i>EJHaem</i> , 2021, 2, 23-24.	0.4	0
15	Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. <i>British Journal of Haematology</i> , 2021, 192, 560-567.	1.2	9
16	Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. <i>Blood Advances</i> , 2021, 5, 1483-1489.	2.5	17
17	Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2021, 384, 842-858.	13.9	388
18	Single-nucleotide Fcγ3 receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 2935-2944.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , 2021, 5, 2945-2957.	2.5	7
20	Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, jnumed.121.262324.	2.8	2
21	Impact of Disease Extent and Distribution on Outcomes in Stage II Follicular Lymphoma Treated with Curative-Intent Radiation Therapy. <i>Blood</i> , 2021, 138, 2431-2431.	0.6	0
22	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. <i>Leukemia</i> , 2020, 34, 522-532.	3.3	26
23	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	0.8	488
24	Validation of a simplified international prognostic score (IPS) in patients with advanced-stage classic Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 122-127.	1.2	9
25	Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. <i>Blood</i> , 2020, 136, 1006-1010.	0.6	15
26	A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. <i>Journal of Hematology and Oncology</i> , 2020, 13, 71.	6.9	82
27	Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2492-2496.	0.6	0
28	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 577-588.	15.2	46
29	Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada. <i>Blood</i> , 2020, 136, 13-15.	0.6	0
30	Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 18-19.	0.6	0
31	Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC). <i>Blood</i> , 2020, 136, 33-34.	0.6	0
32	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. <i>Blood</i> , 2019, 134, 761-764.	0.6	77
33	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019, 3, 2013-2021.	2.5	40
34	High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 481-484.	1.3	10
35	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	0.6	89
36	Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach. <i>Blood</i> , 2019, 134, 2845-2845.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1285-1285.	0.6	9
38	Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). <i>Blood</i> , 2019, 134, 401-401.	0.6	18
39	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
40	Double hit lymphoma: do we need a "double hit"™ of intensive therapy?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1767-1768.	0.6	3
41	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2259-2266.	0.8	107
42	Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?. <i>Current Oncology Reports</i> , 2018, 20, 103.	1.8	9
43	Editor's introduction. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 185-186.	0.7	0
44	Management of relapsed/refractory DLBCL. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 209-216.	0.7	91
45	A tale of two antibodies: obinutuzumab <i>versus</i> rituximab. <i>British Journal of Haematology</i> , 2018, 182, 29-45.	1.2	123
46	Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 324-332.	0.6	32
47	Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2017, 102, e199-e202.	1.7	4
48	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , 2017, 75, 195-203.	1.3	65
49	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	1.7	39
50	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , 2017, 129, 2760-2770.	0.6	112
51	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017, 96, 253-259.	0.8	22
52	Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 711-714.	0.6	7
53	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. <i>British Journal of Haematology</i> , 2017, 176, 234-240.	1.2	20
54	Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-PI risk model. <i>British Journal of Haematology</i> , 2017, 179, 508-510.	1.2	26

#	ARTICLE	IF	CITATIONS
55	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3529-3537.	0.8	333
56	Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: report of the Childhood/Adolescent/Young Adult Cancer Survivors Research Program and the <scp>BC</scp> Cancer Agency Centre for Lymphoid Cancer. <i>British Journal of Haematology</i> , 2016, 172, 757-768.	1.2	38
57	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2016, 34, 3150-3156.	0.8	313
58	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2493-2500.	0.8	56
59	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	3.0	56
60	Novel agents in follicular lymphoma: choosing the best target. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 284-292.	0.9	3
61	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , 2016, 127, 2182-2188.	0.6	145
62	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary <scp>CNS</scp> involvement. <i>British Journal of Haematology</i> , 2016, 175, 876-883.	1.2	34
63	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. <i>Haematologica</i> , 2016, 101, e411-e414.	1.7	11
64	Diffuse Large B-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1179-1194.	0.9	6
65	The Increasing Complexity of Aggressive B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, xiii-xiv.	0.9	0
66	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1081-1093.	5.1	297
67	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 276-282.	0.6	14
68	Cell of origin of transformed follicular lymphoma. <i>Blood</i> , 2015, 126, 2118-2127.	0.6	91
69	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. <i>Blood</i> , 2015, 126, 2646-2649.	0.6	64
70	Rituximab with high-dose methotrexate in primary central nervous system lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1149-1154.	2.0	41
71	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. <i>Blood</i> , 2015, 125, 22-32.	0.6	445
72	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 341-348.	0.2	39

#	ARTICLE	IF	CITATIONS
73	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	0.8	334
74	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <i>Lancet Oncology</i> , 2015, 16, 704-715.	5.1	272
75	Obinutuzumab in hematologic malignancies: Lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015, 41, 784-792.	3.4	52
76	Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Canadian study of 443 patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1041-1046.	2.0	71
77	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20-positive Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3467-3474.	0.8	149
78	Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3978-3978.	0.6	17
79	Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2015, 126, 3950-3950.	0.6	0
80	R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. <i>Haematologica</i> , 2014, 99, 1343-1349.	1.7	79
81	CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. <i>British Journal of Haematology</i> , 2014, 167, 608-617.	1.2	84
82	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , 2014, 123, 837-842.	0.6	693
83	MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. <i>British Journal of Haematology</i> , 2014, 165, 382-391.	1.2	157
84	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. <i>Blood</i> , 2014, 123, 3567-3573.	0.6	76
85	Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 421-426.	1.0	21
86	International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 3383-3388.	0.8	171
87	Reply to L. Wannesson et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 336-337.	0.8	0
88	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. <i>Blood</i> , 2012, 119, 5118-5125.	0.6	145
89	Treatment and Outcomes of Primary Breast Lymphoma. <i>Clinical Breast Cancer</i> , 2012, 12, 412-419.	1.1	46
90	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	0.6	53

#	ARTICLE	IF	CITATIONS
91	Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S82-S91.	2.0	17
92	Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. <i>Cancer</i> , 2012, 118, 4156-4165.	2.0	49
93	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 402-9.	0.9	44
94	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 402-409.	0.9	48
95	CD30 Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1558-1558.	0.6	5
96	The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era. <i>Blood</i> , 2012, 120, 303-303.	0.6	29
97	A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2012, 120, 56-56.	0.6	11
98	A 7-Gene MicroRNA Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis. <i>Blood</i> , 2012, 120, 1586-1586.	0.6	0
99	Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) – A Heterogeneous Disorder with Improved Outcomes in the Modern Era. <i>Blood</i> , 2012, 120, 1602-1602.	0.6	0
100	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	0.6	168
101	Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2011, 29, 1452-1457.	0.8	197
102	Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3396-3401.	0.8	33
103	Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study. <i>Blood</i> , 2011, 118, 269-269.	0.6	18
104	Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era. <i>Blood</i> , 2011, 118, 780-780.	0.6	3
105	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. <i>Haematologica</i> , 2010, 95, 96-101.	1.7	63
106	A decade of R-CHOP. <i>Blood</i> , 2010, 116, 2000-2001.	0.6	17
107	Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. <i>Value in Health</i> , 2010, 13, 703-711.	0.1	25
108	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38

#	ARTICLE	IF	CITATIONS
109	Hypoxia-Inducible Factor-1 $\hat{\pm}$ Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2010, 28, 1017-1024.	0.8	57
110	Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-10.	0.6	53
111	Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment. <i>Blood</i> , 2010, 116, 1751-1751.	0.6	4
112	Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials. <i>Blood</i> , 2010, 116, 417-417.	0.6	2
113	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2010, 116, 2005-2005.	0.6	2
114	The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2010, 116, 4129-4129.	0.6	0
115	Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 800-800.	0.6	0
116	Early detection of patients with poor risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1744-1747.	0.6	18
117	CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. <i>Haematologica</i> , 2009, 94, 423-427.	1.7	53
118	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. <i>Blood</i> , 2009, 113, 3773-3780.	0.6	133
119	R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.. <i>Blood</i> , 2009, 114, 408-408.	0.6	28
120	Alemtuzumab in clinical practice: A British Columbia experience. <i>Leukemia and Lymphoma</i> , 2008, 49, 218-226.	0.6	12
121	Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5165-5169.	0.8	333
122	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 447-454.	0.8	159
123	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Blood</i> , 2008, 111, 5509-5514.	0.6	93
124	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2008, 112, 3425-3433.	0.6	130
125	Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008, 112, 479-479.	0.6	2
126	CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1102-1109.	0.6	63

#	ARTICLE	IF	CITATIONS
127	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2007, 109, 1857-1861.	0.6	1,193
128	Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. <i>Blood</i> , 2007, 109, 4171-4173.	0.6	98
129	FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.. <i>Blood</i> , 2007, 110, 213-213.	0.6	3
130	Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.. <i>Blood</i> , 2007, 110, 787-787.	0.6	16
131	Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.. <i>Blood</i> , 2007, 110, 790-790.	0.6	14
132	Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP.. <i>Blood</i> , 2007, 110, 1559-1559.	0.6	1
133	Treatment of Diffuse Large B-Cell Lymphoma: A Risk-Based Approach. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, S14-S19.	1.4	4
134	Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 295-302.	0.9	40
135	Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. <i>Blood</i> , 2006, 108, 2739-2739.	0.6	0
136	Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R).. <i>Blood</i> , 2006, 108, 2027-2027.	0.6	0
137	Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. <i>Journal of Clinical Oncology</i> , 2005, 23, 5027-5033.	0.8	874
138	Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).. <i>Blood</i> , 2005, 106, 492-492.	0.6	7
139	Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. <i>Oncology</i> , 2005, 19, 26-34.	0.4	29
140	Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.. <i>Blood</i> , 2004, 104, 1407-1407.	0.6	9
141	New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. <i>Annals of Lymphoma</i> , 0, 3, 10-10.	4.5	11
142	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. <i>Leukemia and Lymphoma</i> , 0, , 1-16.	0.6	1